Danaher (NYSE:DHR) Now Covered by Stephens

by · The Markets Daily

Investment analysts at Stephens initiated coverage on shares of Danaher (NYSE:DHR – Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $315.00 price target on the conglomerate’s stock. Stephens’ price objective would suggest a potential upside of 14.98% from the stock’s current price.

A number of other equities analysts have also recently issued reports on DHR. Leerink Partners upped their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Robert W. Baird raised their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $282.12.

View Our Latest Analysis on DHR

Danaher Trading Down 0.2 %

Shares of DHR stock opened at $273.95 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a market cap of $202.91 billion, a PE ratio of 46.43, a P/E/G ratio of 4.55 and a beta of 0.83. The stock’s fifty day moving average price is $271.14 and its two-hundred day moving average price is $258.35.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $2.05 earnings per share. Equities analysts predict that Danaher will post 7.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Large investors have recently made changes to their positions in the company. Benjamin Edwards Inc. boosted its holdings in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. lifted its holdings in shares of Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares in the last quarter. Trust Co of Kansas grew its position in Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the period. Abacus Planning Group Inc. increased its stake in Danaher by 0.7% during the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares in the last quarter. Finally, Certified Advisory Corp raised its holdings in Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after buying an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also